This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: Cardinal Health (CAH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Cardinal Health (CAH) a Solid Pick for Value Investors?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for DVP
Here's Why You Should Hold on to Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Cardinal (CAH) Upgraded to Buy: Here's Why
by Zacks Equity Research
Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Top Ranked Income Stocks to Buy for January 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 6th.
Top Ranked Income Stocks to Buy for January 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 2nd.
Here's Why You Should Hold on to Intuitive Surgical for Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction remains a concern.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CAH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVP
Top Ranked Income Stocks to Buy for December 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 27th.
Top Ranked Income Stocks to Buy for December 20th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 20th.
Top Ranked Income Stocks to Buy for December 19th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, December 19th.
Here's Why You Should Invest in Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal (CAH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cardinal (CAH) Up 3.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Deep Value ETF (DVP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DVP
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, Veeva (VEEV) raises its fiscal 2020 revenue guidance.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.